prof. Barbara Jereczek-Fossa
@BarbaraJereczek
Followers
531
Following
1K
Statuses
112
MD PhD, Radiation Oncologist, Full Professor of Milan University, Chief of Radiotherapy Dept, European Inst. of Oncology
Milano, Lombardia
Joined December 2019
Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study - The Lancet Oncology 📍call to action to ensure access to live-saving treatment
2
5
28
Understanding the Disruptive Potential of MDT in Metastatic Prostate Cancer Treatment, Exploring Hypotheses for Future Studies #ASCODailyNews
@ASCO
@GiuliaMarvaso84
@FMastroleoMD
@piet_ost
@ChadTangMD SimonaBorghesi
4
7
42
Congratulations to new radiation oncologists and a huge thank you to the entire faculty of our School! @LaStatale
@IEOufficiale
Oggi celebriamo 8 nuovi medici che concludono la loro specializzazione in Radioterapia Oncologica! I titoli delle loro tesi spaziano da trattamenti innovativi per le metastasi cerebrali a nuovi approcci nella gestione multidisciplinare dei tumori. Congratulazioni! 💙 @unimi
0
0
11
Kick-off meeting for Jane-2: Networks of Expertise on Cancer is underway in Milan, Italy. An EU Joint Action uniting experts and stakeholders to advance cancer care—with radiation oncology onboard 👍🏻
0
0
6
RT @APCCC_Lugano: Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials out on the R…
0
8
0
RT @FelixEhretMD: Here’s our multicenter analysis on SBRT for pulmonary metastases in oligometastatic head and neck cancer patients - A gre…
0
7
0
RT @ESTRO_RT: Become an ESTRO Member in 2025! 🌟 In 2024, we were just 21 members away from 10,000! Let’s break the milestone this year! 🚀 J…
0
5
0
RT @ESTRO_RT: 🚀Ready to embark on your journey? Navigate ESTRO 2025 with ease! Discover tailored sessions that match your interests. 👉More…
0
8
0
RT @ESTRO_RT: 🌟 Happy New Year from ESTRO! 🌟 Prof Matthias Guckenberger shares 2024 highlights and his vision for 2025 in this inspiring me…
0
5
0
📣Urethra: an important organ at risk especially for DIL boosting or re-irradiation. Useful international effort to maintain low toxicity of the prostate radiotherapy.
💥 Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey
0
2
13
RT @ESTRO_RT: 🎄✨ Season's Greetings from ESTRO! ✨🎄 As we wrap up another remarkable year, we extend our heartfelt thanks to our community o…
0
5
0
RT @Mat_Guc: @ESTRO_RT power team @AnnaKirby17 and @BarbaraJereczek as past-president and president-elect Thanks you so much for your 💪…
0
6
0
RT @NiuSanford: RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, a…
0
70
0
RT @urotoday: #RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. @GiuliaMarvaso84 shares findings from the RADIOSA trial,…
0
35
0
RT @Icro_Meattini: Single-modality endocrine therapy versus #radiotherapy after breast-conserving surgery in women aged 70 years and older…
0
46
0
RadOncs and MedOncs working togheter for the best of our patients. One of many examples. @curijoey
@IEOufficiale
🚨🔥Huge effort to customize treatments and preserve QoL on well tolerated systemic therapies at @IEOufficiale Patient (ultra)selection is 🔑 to manage oligoPD disease with SBRT and continue the same systemic tx Don’t miss the concomitant publication on EJC (N=129)
3
3
19
RT @gusviani: 🎙EUROPA Trial: ☢️ shows ⬆️ HRQOL and ⬇️⬇️ side effects vs. endocrine therapy in women 70+ with early-stage breast cancer❗️ @…
0
48
0